Funding for this research was provided by:
European Regional Development Fund (087-1.1-18)
Universität zu Lübeck
Received: 18 September 2020
Accepted: 29 March 2021
First Online: 9 April 2021
: The SURF-ROGG trial was approved by the local ethics committee (University of Lübeck, no. 20–311). The trial is performed according to the Declaration of Helsinki and the principles of Good Clinical Practice (GCP). Patients are included only after written informed consent.
: Not applicable.
: Dirk Rades is associate editor of BMC Cancer. Otherwise, no competing interests exist regarding this trial.